Acquisition of the branded non-oncology prescription formulations business of Khandelwal Laboratories Private…

Aurobindo Pharma Limited's wholly owned subsidiary, Auro Pharma Limited, has approved the acquisition of the non-oncology prescription formulations business of Khandelwal Laboratories Private Limited. This acquisition will be conducted on a going concern basis through a Business Transfer Agreement. Further details are provided in the attached Annexure A.

An acquisition spends cash or issues shares today for earnings that arrive later, so the price paid and the funding route decide whether holders gain.

• Consideration and how it is funded
• Revenue and profit of the target
• Expected completion date
• This approval has been received from Eugia Unit-I and is expected to be launched in Q1FY27. (management committed by Q1 FY27)